RxDoctor Payments DataLook up a doctor →

Sanjay Kaul, MD

Cardiology · Los Angeles, CANPI 1790713071

Payments from drug & device makers

$1,119,151in general payments, 2019–2025

Across 326 payments — averaging $3432.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$289K
  • Bayer$69K
  • Novo Nordisk$64K
  • GSK$62K
  • Boehringer Ingelheim$49K
  • Boehringer Ingelheim (phil.) Inc.$43K
  • plus $543K from 46 others
$11,850in research payments, 2019–2025

Across 1 payment — averaging $11,850 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$12K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim International GmbH54$288,649
Bayer48$69,407
Novo Nordisk21$63,519
GSK23$62,350
Boehringer Ingelheim19$48,969
Boehringer Ingelheim (phil.) Inc.3$43,375
AbbVie13$40,746
Boehringer Ingelheim MENA (scientific Office) Fz-llc11$36,365
Novartis12$27,567
Travere Therapeutics, Inc.7$27,487
Medtronic(2 entities)9$25,794
Sarepta Therapeutics, Inc.1$25,000
Vertex2$24,000
Amgen16$22,078
Takeda Pharmaceuticals U.S.A., Inc.2$21,200
AstraZeneca3$18,219
Janssen Research & Development, LLC1$17,000
Abbott11$16,694
Intercept Pharmaceuticals, Inc.3$16,401
Eisai Inc.1$16,000
Alnylam Pharmaceuticals Inc.1$16,000
H. Lundbeck A S1$15,300
Ardelyx, Inc.1$14,450
Pharmacyclics LLC, An Abbvie Company1$14,400
Acrotech Biopharma Inc.1$14,400
Endologix LLC1$14,400
Merck12$13,998
Gilead1$13,600
Edwards Lifesciences3$13,020
Neovasc Medical Inc1$12,000
Bard Peripheral Vascular, Inc.1$12,000
Ipsen Bioscience Inc.1$10,500
Akebia Therapeutics Inc1$9,800
Regeneron3$8,800
Eli Lilly4$6,200
Boehringer Ingelheim India Pvt. Ltd.2$5,700
Boehringer Ingelheim Middle East & Africa GmbH1$3,625
Boehringer Ingelheim Singapore Pte. Ltd.1$3,530
Boehringer Ingelheim Saudi Arabia Trading1$3,480
Otsuka Pharmaceutical Development & Commercialization, Inc.7$1,372
Heron Therapeutics, Inc.1$1,300
Sanofi-aventis U.S. LLC4$85
Lilly USA, LLC3$84
Esperion Therapeutics, Inc.2$57
Heartflow, Inc.2$43
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$41
Lexicon Pharmaceuticals, Inc.1$37
Pfizer2$35
Phathom Pharmaceuticals, Inc.1$22
Daiichi Sankyo Inc.1$19
Philips North America LLC1$18
E.r. Squibb & Sons, L.L.C.1$15

How this compares

$1,119,151 in reported general payments places this provider in the 95th percentile of 156 cardiology providers in California.

See all cardiology providers in California

Medicare billing

Part B allowed, 2024
$294,540
Medicare patients
212
Services billed
13,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →